USA flag logo/image

An Official Website of the United States Government

POSITIVE SELECTION SYSTEMS USING MARKER GENES

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
76315
Program Year/Program:
2005 / SBIR
Agency Tracking Number:
GM074315
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
MARKER GENE TECHNOLOGIES, INC
1850 MILLRACE DRIVE 1850 MILLRACE DRIVE EUGENE, OR 97403 1992
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: Yes
 
Phase 1
Fiscal Year: 2005
Title: POSITIVE SELECTION SYSTEMS USING MARKER GENES
Agency: HHS
Contract: 1R43GM074315-01
Award Amount: $99,879.00
 

Abstract:

This Small Business Innovation Research Phase I project aims to investigate the feasibility of developing new compounds capable of utilizing common marker gene expression in transformed cells to control the growth and character of cells in cell culture and live tissue applications. If successful, the proposed research will provide breakthroughs needed to advance the promising medical uses of recombinant genes. In Phase I of this project, Marker Gene Technologies proposes to establish the feasibility of the technology by preparing new galactoside and Cephalosporin conjugates of common growth regulators, drugs and enzyme activators, for administration to animal cells or bacteria that contain either the beta-galactosidase (lacZ) or ampicillin resistance (Beta-lactamase, amp) genes as gene fusion markers. These new conjugates will be used to provide innovative methods of utilizing these fusion systems in transformed cells - to select for transgenic cells in a non-destructive fashion. In Phase I, the new conjugates will be assayed in vitro for their ability to cause specific and localized improvement of cell growth and to deliver the active agents in a cell- or tissue-specific manner. In Phase II, the conjugates will be further tested in a variety of significant medical applications. The success of this project opens up enormous commercial possibilities in the fields of cell selection, medical intervention in genetic diseases, immunotherapy for cancer treatment, biotechnological production of new proteins and drugs in cell-culture systems, and bacterial screening strategies, and the conjugates prepared can be marketed in these areas. In addition, it contributes new information and techniques for basic cell-biology research.

Principal Investigator:

John J. Naleway
5413423760
JNALEWAY@UOREGON.EDU

Business Contact:

Alisa Naleway
5413423760
ALISANALEWAY@HOTMAIL.COM
Small Business Information at Submission:

Marker Gene Technologies
Marker Gene Technologies, Inc. University Of Oregon Riverfront Research Park Eugene, OR 97403

EIN/Tax ID: 931228900
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No